Progress in research on therapy of ovarian cancer with monoclonal antibodies
Ovarian cancer is the most lethal gynecological malignancy. One possible treatment strategy that may improve the prognosis of patients is the use of monoclonal antibodies (mAbs) which can selectively target tumor cells expressing tumor-associated antigens, and offer potential benefits such as avoiding the cytotoxic effect of traditional chemotherapy on normal tissues. Based on the promising results of preclinical studies, various mAb are currently being evaluated in patients with ovarian cancer, some of which have already demonstrated favorable clinical outcomes in phase I/II studies. This paper reviews the progress in research on therapy of ovarian cancer with mAbs.